Exclusion criteria included a previous diagnosis of diabetes, a glycated hemoglobin level of ≥ 6.5% (48 mmol per mole) measured at screening, treatment with any glucose-lowering medication or GLP-1 receptor agonist within the previous 90 days, New York Heart Association class IV heart failure, end-stage kidney disease or dialysis, cardiovascular or neurologic event within 60 days, or if they planned to undergo coronary, carotid, or peripheral revascularization. This evidence concerns the gene GLP1R and diabetes mellitus.